Similarly, a meta-analysis conducted by Gragnano et al., employing pooled patient-level data, also failed to demonstrate a significant effect of short-DAPT followed by P2Y12 inhibitor monotherapy in relation to ischemic composite endpoints (comprising all-cause death, myocardial infarction, and stroke) when compared to the conventional DAPT strategy in both complex and non-complex PCI patients (complex PCI, hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.64–1.19; non-complex PCI, HR 0.91, 95% CI 0.76–1.09)24. Here, P2RY12 is linked to stroke disorder.